SARS‐CoV‐2 infection in lung transplant recipients induces circulating exosomes with SARS‐CoV‐2 spike protein S2

Bansal, Sandhya; Tokman, Sofya; Fleming, Timothy P.; Maine, Gabriel N.; Sanborn, Kristina; Hachem, Ramsey R.; Bharat, Ankit; Smith, Michael A.; Bremner, Ross M.; Mohanakumar, Thalachallour

doi:10.1002/ctm2.576

Cited by 13 publications

(21 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CLEC3B is also suggested as a severity biomarker and potential drug target for COVID‐19 [ 54 ]. Another biomarker candidate for severity biomarker for COVID‐19, MST1 is predominantly expressed specifically in immune cells and plays an important role in the cytotoxicity of the cells in response to viral response [ 55 , 56 ]. It was proposed as a potential early detection biomarker for colorectal cancer and might be useful for predicting the progression of breast cancer [ 57 , 58 ].…”

Section: Discussionmentioning

confidence: 99%

Plasma proteomics identify potential severity biomarkers from COVID‐19 associated network

Sahin

Yurtseven

Dadmand

et al. 2022

Proteomics Clinical Apps

View full text Add to dashboard Cite

Purpose Coronavirus disease 2019 (COVID‐19) continues to threaten public health globally. Severe acute respiratory coronavirus type 2 (SARS‐CoV‐2) infection‐dependent alterations in the host cell signaling network may unveil potential target proteins and pathways for therapeutic strategies. In this study, we aim to define early severity biomarkers and monitor altered pathways in the course of SARS‐CoV‐2 infection. Experimental Design We systematically analyzed plasma proteomes of COVID‐19 patients from Turkey by using mass spectrometry. Different severity grades (moderate, severe, and critical) and periods of disease (early, inflammatory, and recovery) are monitored. Significant alterations in protein expressions are used to reconstruct the COVID‐19 associated network that was further extended to connect viral and host proteins. Results Across all COVID‐19 patients, 111 differentially expressed proteins were found, of which 28 proteins were unique to our study mainly enriching in immunoglobulin production. By monitoring different severity grades and periods of disease, CLEC3B, MST1, and ITIH2 were identified as potential early predictors of COVID‐19 severity. Most importantly, we extended the COVID‐19 associated network with viral proteins and showed the connectedness of viral proteins with human proteins. The most connected viral protein ORF8, which has a role in immune evasion, targets many host proteins tightly connected to the deregulated human plasma proteins. Conclusions and Clinical Relevance Plasma proteomes from critical patients are intrinsically clustered in a distinct group than severe and moderate patients. Importantly, we did not recover any grouping based on the infection period, suggesting their distinct proteome even in the recovery phase. The new potential early severity markers can be further studied for their value in the clinics to monitor COVID‐19 prognosis. Beyond the list of plasma proteins, our disease‐associated network unravels altered pathways, and the possible therapeutic targets in SARS‐CoV‐2 infection by connecting human and viral proteins. Follow‐up studies on the disease associated network that we propose here will be useful to determine molecular details of viral perturbation and to address how the infection affects human physiology.

show abstract

Section: Discussionmentioning

confidence: 99%

Plasma proteomics identify potential severity biomarkers from COVID‐19 associated network

Sahin

Yurtseven

Dadmand

et al. 2022

Proteomics Clinical Apps

View full text Add to dashboard Cite

show abstract

“…The work does not explain in detail the mechanism of the presence of receptors in the urine but suggest that AT1R can be expressed in vascular tissues throughout the body and may be filtered to some extent through the glomerulus. On the other hand, in the study by Bansal et al [ 19 ], the concentration of the AT1R receptor in serum exosomes was determined by Western blot and densitometry analysis.…”

Section: Discussionmentioning

confidence: 99%

Does the Serum Concentration of Angiotensin II Type 1 Receptor Have an Effect on the Severity of COVID-19? A Prospective Preliminary Observational Study among Healthcare Professionals

Janc

Suchański

Mierzchała-Pasierb

et al. 2022

JCM

View full text Add to dashboard Cite

SARS-CoV-2 is a virus that causes severe respiratory distress syndrome. The pathophysiology of COVID-19 is related to the renin–angiotensin system (RAS). SARS-CoV-2, a vector of COVID-19, uses angiotensin-converting enzyme 2 (ACE-2), which is highly expressed in human lung tissue, nasal cavity, and oral mucosa, to gain access into human cells. After entering the cell, SARS-CoV-2 inhibits ACE-2, thus favouring the ACE/Ang II/angiotensin II type 1 receptor (AT1R) axis, which plays a role in the development of acute lung injury (ALI). This study aimed to analyse the influence of angiotensin 1 receptor (AT1R) levels in the serum on the course of the severity of symptoms in healthcare professionals who had a SARS-CoV-2 infection. This prospective observational study was conducted on a group of 82 participants. The study group included physicians and nurses who had a COVID-19 infection confirmed by real-time reverse transcription-polymerase chain reaction (RT-PCR) test for SARS-CoV-2. The control group consisted of healthy medical professionals who had not had a SARS-CoV-2 infection or who had no symptoms of COVID-19 and who tested negative for SARS-CoV-2 on the day of examination. We analysed the correlation between AT1R concentration and the severity of COVID-19, as well as with sex, age, blood group, and comorbidities. There were no statistically significant differences in the mean values of AT1R concentration in the recovered individuals and the non-COVID-19 subjects (3.29 vs. 3.76 ng/mL; p = 0.32). The ROC curve for the AT1R assay showed an optimal cut-off point of 1.33 (AUC = 0.44; 95% CI = 0.32–0.57; p = 0.37). There was also no correlation between AT1R concentration and the severity of symptoms associated with COVID-19. Blood type analysis showed statistically significantly lower levels of AT1R in COVID-19-recovered participants with blood group A than in those with blood group O. In conclusion, AT1R concentration does not affect the severity of symptoms associated with COVID-19 among healthcare professionals.

show abstract

“…Indeed, SARS-CoV-2 RNA was detected in exosomes from patients with COVID-19, but not healthy subjects [84]. SARS-CoV-2-S antigen S2 and nucleocapsid proteins are present in the plasma exosomes from symptomatic patients with COVID-19, and immunization of mice with these human-derived exosomes induced the production of antibodies to SARS-CoV-2-S [91].…”

Section: Exosomesmentioning

confidence: 96%

Neurological aspects of SARS-CoV-2 infection: lipoproteins and exosomes as Trojan horses

Lam¹,

Huang²,

Shui³

2022

Trends in Endocrinology & Metabolism

View full text Add to dashboard Cite

SARS‐CoV‐2 infection in lung transplant recipients induces circulating exosomes with SARS‐CoV‐2 spike protein S2

Cited by 13 publications

References 9 publications

Plasma proteomics identify potential severity biomarkers from COVID‐19 associated network

Plasma proteomics identify potential severity biomarkers from COVID‐19 associated network

Does the Serum Concentration of Angiotensin II Type 1 Receptor Have an Effect on the Severity of COVID-19? A Prospective Preliminary Observational Study among Healthcare Professionals

Neurological aspects of SARS-CoV-2 infection: lipoproteins and exosomes as Trojan horses

Contact Info

Product

Resources

About